Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Cardiac Hypertrophy: early-phase trial registry

1 of 2 indexed Cardiac Hypertrophy trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Cardiac Hypertrophy: 2 US clinical trials tracked, 1 recruiting.

Cardiac Hypertrophy is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Weill Medical College of Cornell University, running 1 of these trials.

Enrollment posture brief

Registry condition cardiac-hypertrophy

OPEN 1 | RECR 50% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Cardiac Hypertrophy (this)50%
Open-enrollment share among volume-matched conditions near Cardiac Hypertrophy

Cardiac Hypertrophy lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Cardiac Hypertrophy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Cardiac Hypertrophy is recruiting above its size-band peers.

    1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Named interventions

Most-linked intervention names on Cardiac Hypertrophy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Serology Biological
1 trials
AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN Biological
1 trials
Prednisone Drug
1 trials
Echocardiogram Procedure
1 trials

US sites by state

Facility locations filed on Cardiac Hypertrophy trials. A trial with sites in several states counts in each.

New York 1 trials
Colorado 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Cardiac Hypertrophy page

2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cardiac Hypertrophy condition card totals 2 registered trials; most-linked intervention Serology; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.